GT Biopharma Inc Cash Flow-to-Debt Ratio
GT Biopharma Inc cash flow-to-debt ratio. GT Biopharma Inc (GTBP) has a Cash Flow-to-Debt Ratio of -1.92x as of June 2026, meaning its operating cash flow of $-4.26 Million could theoretically repay -2% of its total liabilities ($2.22 Million) in one year. Check cash flow quality index of GT Biopharma Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GT Biopharma Inc (1985–2025)
Cash flow-to-debt ratio of GT Biopharma Inc from 1985 to 2025. Historical debt coverage capacity for GT Biopharma Inc across 41 annual periods. Check GTBP capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
GT Biopharma Inc Cash Flow-to-Debt Ratio by Year (1985–2025)
GT Biopharma Inc cash flow-to-debt ratio by year from 1985 to 2025. Year-by-year debt coverage analysis for GT Biopharma Inc. For the full cash flow conversion analysis, see GT Biopharma Inc (GTBP) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.57x | $-12.91 Million | $2.32 Million | ▼ -154.7% |
| 2024 | -2.19x | $-12.90 Million | $5.90 Million | ▼ -63.8% |
| 2023 | -1.33x | $-8.85 Million | $6.63 Million | ▲ +56.1% |
| 2022 | -3.04x | $-15.22 Million | $5.00 Million | ▼ -100.0% |
| 2021 | -1.52x | $-15.61 Million | $10.26 Million | ▼ -635.1% |
| 2020 | -0.21x | $-7.26 Million | $35.09 Million | ▼ -11.4% |
| 2019 | -0.19x | $-3.66 Million | $19.71 Million | ▲ +75.6% |
| 2018 | -0.76x | $-10.68 Million | $14.03 Million | ▲ +62.5% |
| 2017 | -2.03x | $-5.43 Million | $2.68 Million | ▼ -1890.0% |
| 2016 | -0.10x | $-1.93 Million | $18.95 Million | ▼ -10.7% |
| 2015 | -0.09x | $-4.66 Million | $50.62 Million | ▼ -60.2% |
| 2014 | -0.06x | $-1.75 Million | $30.46 Million | ▲ +15.8% |
| 2013 | -0.07x | $-442.00K | $6.48 Million | ▲ +54.7% |
| 2012 | -0.15x | $-987.00K | $6.56 Million | ▲ +18.3% |
| 2011 | -0.18x | $-963.00K | $5.23 Million | ▲ +32.2% |
| 2010 | -0.27x | $-1.53 Million | $5.65 Million | ▼ -105.9% |
| 2009 | -0.13x | $-937.00K | $7.11 Million | ▼ -233.1% |
| 2008 | -0.04x | $-169.00K | $4.27 Million | ▲ +52.7% |
| 2007 | -0.08x | $-270.00K | $3.23 Million | ▲ +2.7% |
| 2006 | -0.09x | $-671.00K | $7.80 Million | ▲ +82.5% |
| 2005 | -0.49x | $-2.09 Million | $4.27 Million | ▼ -26.1% |
| 2004 | -0.39x | $-1.04 Million | $2.68 Million | ▼ -85.6% |
| 2003 | -0.21x | $-229.00K | $1.09 Million | ▲ +84.1% |
| 2002 | -1.31x | $-1.01 Million | $767.00K | ▼ -9.6% |
| 2001 | -1.20x | $-1.43 Million | $1.19 Million | ▲ +52.1% |
| 2000 | -2.50x | $-3.89 Million | $1.55 Million | ▼ -152.3% |
| 1999 | -0.99x | $-2.48 Million | $2.50 Million | ▲ +23.6% |
| 1998 | -1.30x | $-5.20 Million | $4.00 Million | ▼ -57.1% |
| 1997 | -0.83x | $-4.80 Million | $5.80 Million | ▲ +32.6% |
| 1996 | -1.23x | $-4.30 Million | $3.50 Million | ▼ -29.8% |
| 1995 | -0.95x | $-5.30 Million | $5.60 Million | ▼ -1164.7% |
| 1994 | 0.09x | $400.00K | $4.50 Million | ▲ +101.7% |
| 1993 | -5.33x | $-1.60 Million | $300.00K | ▼ -540.0% |
| 1992 | -0.83x | $-500.00K | $600.00K | ▲ +16.7% |
| 1991 | -1.00x | $-200.00K | $200.00K | ▼ -122.2% |
| 1990 | 4.50x | $900.00K | $200.00K | ▲ +221.4% |
| 1989 | 1.40x | $700.00K | $500.00K | ▲ +320.0% |
| 1988 | 0.33x | $100.00K | $300.00K | ▲ +33.3% |
| 1987 | 0.25x | $50.00K | $200.00K | ▲ +131.3% |
| 1986 | -0.80x | $-400.00K | $500.00K | ▲ +73.3% |
| 1985 | -3.00x | $-300.00K | $100.00K | — |